ENSYSCE BIOSCIENCES INC ENSC
COM NEW · Common Stock · CUSIP 293602504
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersLa Jolla, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 3.0m as of 2025-08-12, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $2.23.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2024 | 9 |
| Q1 2025 | 10 |
| Q2 2025 | 12 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2025 | 6 | 1 |
| Q2 2025 | 6 | 3 |
Biggest buyers
| GEODE CAPITAL MANAGEMENT, LLC | New | +10.2k |
| SBI Securities Co., Ltd. | New | +2.3k |
| Tower Research Capital LLC (TRC) | Added | +928 |
| MORGAN STANLEY | New | +378 |
| RAYMOND JAMES FINANCIAL INC | New | +94 |
| BANK OF AMERICA CORP /DE/ | Added | +11 |
Biggest sellers
| Murchinson Ltd. | Sold out | -140.0k |
| SABBY MANAGEMENT, LLC | Sold out | -47.0k |
| UBS Group AG | Reduced | -954 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
GOWER BOB G
13D · may seek influence
filed 2026-08-18
Stated purposeThe Reporting Person acquired the securities in connection with his service as a director of the Issuer and for investment purposes. In his capacity as the Chairman of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the Issuer's Insider Trading Policy, the Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances. Except as set forth herein, the Reporting Person does not have any present plans or proposals at this time that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Sup… Full filing |
6.1% |
Insider purchases and sales in Q2 2025
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2025.
Holders, Q2 2025
| Manager | Shares | Change |
|---|---|---|
| PERCEPTIVE ADVISORS LLC 0.01% of their portfolio | 86.7k $193.3k | Unchanged |
| ADAGE CAPITAL PARTNERS GP, L.L.C. 0.00% of their portfolio | 74.7k $166.6k | Unchanged |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 10.2k $22.7k | New |
| FNY Investment Advisers, LLC 0.00% of their portfolio | 3.0k $6.0k | Unchanged |
| SBI Securities Co., Ltd. 0.00% of their portfolio | 2.3k $5.2k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 1.4k $3.1k | Added +928 |
| MORGAN STANLEY 0.00% of their portfolio | 378 $843 | New |
| UBS Group AG 0.00% of their portfolio | 354 $789 | Reduced -954 |
| RAYMOND JAMES FINANCIAL INC 0.00% of their portfolio | 94 $210 | New |
| BlackRock, Inc. 0.00% of their portfolio | 65 $145 | Unchanged |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 19 $42 | Added +11 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. — of their portfolio | 0 $0 | Unchanged |